Table 5 Comparison of [18F]FDG PET/MRI with ceMRI and/or ceCT for patient-based T, N and M staging, detection of residual disease after neoadjuvant chemotherapy and detection of recurrence
From: Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer
[18F]FDG PET/MRI (95% CI) | ceMRI and ceCT (95% CI) | P | |
|---|---|---|---|
Primary tumor | |||
Sensitivity | 97.4% (0.90–1.00) (37/38) | 97.4% (0.89–1.00) (37/38) | |
Specificity | 86.2% (0.77–0.89) (25/29) | 58.6% (0.48–0.61) (17/29) | |
Accuracy | 92.5% (0.84–0.95) (62/67) | 80.6% (0.72–0.83) (54/67) | 0.01 |
T staging | |||
Accuracy | 96.4% (0.96–0.96) (54/56) | 92.9% (0.93–0.93) (52/56) | 0.48 |
T2a (growth into uterus, fallopian tubes, or ovaries) | |||
Sensitivity | 100% (0.43–1.00) (2/2) | 50% (0.11–0.50) (1/2) | |
Specificity | 100% (0.96–1.00) (30/30) | 100% (0.97–1.00) (30/30) | |
Accuracy | 100% (0.93–1.00) (32/32) | 96.9% (0.92–0.97) (31/32) | 1.00 |
T2b (growth into other nearby pelvic organs such as bladder, sigmoid colon, or rectum) | |||
Sensitivity | 0% (0.00–0.00) (0/1) | 0% (0.00–0.00) (0/1) | |
Specificity | 100% (1.00–1.00) (31/31) | 100% (1.00–1.00) (31/31) | |
Accuracy | 96.9% (0.97–0.97) (31/32) | 96.9% (0.97–0.97) (31/32) | 1.00 |
T3b (growth into organs outside the pelvis, but ≤ 2 cm across) | |||
Sensitivity | 95.5% (0.86–0.96) (21/22) | 90.9% (0.81–0.91) (20/22) | |
Specificity | 100% (0.94–1.00) (33/33) | 100% (0.93–1.00) (33/33) | |
Accuracy | 98.2% (0.91–0.98) (54/55) | 96.4% (0.88–0.96) (53/55) | 1.00 |
T3c (growth into organs outside the pelvis, > 2 cm across) | |||
Sensitivity | 100% (0.92–1.00) (21/21) | 100% (0.92–1.00) (21/21) | |
Specificity | 100% (0.95–1.00) (34/34) | 100% (0.95–1.00) (34/34) | |
Accuracy | 100% (0.94–1.00) (55/55) | 100% (0.94–1.00) (55/55) | 0.00 |
N staging | |||
Sensitivity | 100% (0.74–1.00) (6/6) | 33.3% (0.12–0.33) (2/6) | |
Specificity | 100% (0.93–1.00) (21/21) | 100% (0.94–1.00) (21/21) | |
Accuracy | 100% (0.88–1.00) (27/27) | 85.2% (0.76–0.85) (23/27) | 0.13 |
M staging | |||
Sensitivity | 100% (0.94–1.00) (12/12) | 25.0% (0.19–0.25) (3/12) | |
Specificity | 100% (0.25–1.00) (1/1) | 100% (0.22–1.00) (1/1) | |
Accuracy | 100% (0.88–1.00) (13/13) | 30.8% (0.19–0.31) (4/13) | < 0.01 |
Evaluation of residual disease for interval debulking surgery after neoadjuvant chemotherapy | |||
Sensitivity | 71.4% (0.71–0.71) (5/7) | 57.1% (0.57–0.57) (4/7) | |
Specificity | 0% (0.00–0.00) (0/0) | 0% (0.00–0.00) (0/0) | |
Accuracy | 71.4% (0.71–0.71) (5/7) | 57.1% (0.57–0.57) (4/7) | 1.00 |
Evaluation of recurrence | |||
Sensitivity | 100% (0.88–1.00) (9/9) | 88.9% (0.76–0.89) (8/9) | |
Specificity | 100% (0.44–1.00) (2/2) | 100% (0.40–1.00) (2/2) | |
Accuracy | 100% (0.80–1.00) (11/11) | 90.9% (0.69–0.91) (10/11) | 1.00 |